status: Recognised & Endorsed

Chair (s): Juan Bicarregui, Anne Cambon-Thomsen, Ingrid Dillo, Natalie Harrower, Sarah Jones, Mark Leggott, Priyanka Pillai

Group Email: [group_email]

Secretariat Liaison: enquiries@rd-alliance.org


 

I.  RDA COVID-19 Working Group Objectives

II.  Group & Website Navigation

III.  Weekly Webinar RDA COVID-19 Updates - Completed

 


I.  RDA COVID-19 Working Group Objectives

The overarching objectives of this Working Group (WG) are:

  1.  To clearly define detailed guidelines on data sharing under the present COVID-19 circumstances to help stakeholders follow best practices to maximize the efficiency of their work,

  2.  To develop guidelines for policymakers to maximise timely data sharing and appropriate responses in such health emergencies, and

  3.  To address the interests of researchers, policy makers, funders, publishers, and providers of data sharing infrastructures.

The group thus far has developed detailed guidelines on the deposit of different data sources in any common data hub or platform. The guidelines aim at developing a system for data sharing in public health emergencies that supports scientific research and policy making, including an overarching framework, common tools and processes, and principles that can be embedded in research practice. The guidelines address general aspects related to the principles the data should adhere to (FAIR and other principles), as well as specificities related to four thematic and four overarching areas (below).

 

 

The COVID-19 WG, from April 1st through June 30th, 2020, created more than five releases of the recommendations and guidelines, leading to the final endorsed version, "RDA COVID-19 Recommendations and Guidelines for Data Sharing," with ongoing efforts to add and review materials:

  1. The main guidelines document highlights the primary data sharing resources in four areas, each with different data types, and four cross-cutting themes (community participation, Indigenous population data, legal and ethics, software). Other areas may be added, in future iterations, as the effort proceeds.
    1. Clinical

    2. Omics

    3. Epidemiology

    4. Social Sciences

    5. Community Participation

    6. Indigenous Data

    7. Legal and Ethical

    8. Software

  2. A set of Resource lists in each of these areas, compiled in a publicly available Zotero collection.

  3. A Decision Tree tool to facilitate navigation to specific Resources.

  4. Supporting outputs from some of the subgroups described above.

This Working Group operates according to the RDA guiding principles of Openness, Consensus, Balance, Harmonization, Community-driven, Non-profit and technology-neutral and is OPEN TO ALL. This group is part of the joint activities carried out by CODATA, GO FAIR, RDA and WDS under their Data Together statement.


 


II.  Group & Website Navigation

If you would like to review and contribute to content pertaining to the RDA COVID-19 WG initiative, please do the following:

  1. Become a member of the RDA.
  2. Join the main COVID-19 WG by clicking the "Join Group" link. This will enroll you in the email list for overall updates on the initiative, including announcements regarding the update webinars.
  3. Join the COVID-19 sub-group according to your expertise and interest; follow the links below to find your sub-group(s) and then click the "Join Group" link:
    1. Clinical

    2. Omics

    3. Epidemiology

    4. Social Sciences

    5. Community Participation

    6. Indigenous Data

    7. Legal and Ethical

    8. Software

Helpful information can be found on the main COVID-19 WG wiki, including Q&As from the finished webinar series and how to submit resources for the Zotero catalogue output. Updates and discussions on the overarching COVID-19 group can be found within the Posts section of the wiki, including all emails sent via the main WG's mailing list. Update webinars and related meetings for the overall group can be found at Events.

 

Sub-groups will organize their specific wiki pages and processes according to their group preferences, but in general, the structure is the same as for the main WG's webpages. Please reach out to the sub-group moderators or use the applicable email list for more information; see the Working & Sub-Group Organization wiki page for contact information.

 

To provide feedback on the RDA COVID-19 outputs under review:

Materials under development can be reviewed in the Outputs section of this webpage; be sure to select the most current document version that is attached for review, and provide comments using the "Add new comment" link below the attachments.

 


III.  Weekly Webinar RDA COVID-19 Updates

The weekly "RDA COVID-19 Update Webinar" occurred almost every Tuesday at 11:00 am Universal Time (UTC), and provided updates on the overarching COVID-19, Legal and Ethical, Research Software, Community Participation Working Groups, Indigenous Data contribution, and the four research themes (clinical, omics, epidemiology, social sciences), along with an opportunity for members to ask questions. Recordings and presentations from these sessions are posted on the Events meeting links.

 

File Repository

09
June
2020

RDA COVID19 Webinar Slides 9 June 2020

by Hilary Hanahoe

RDA COVID19 Presentation slides from 5th release overview and highlights webinar - 9 June 2020 11 UTC

AttachmentSize
File COVID19-webinar-9June-2020.pptx5.71 MB
26
May
2020

RDA COVID19 Webinar Slides 26 May 2020

by Hilary Hanahoe

RDA COVID19 Presentation slides from Update and Status webinar - 26 May 2020 11 UTC

AttachmentSize
File COVID19-webinar-26May-2020.pptx6.03 MB
12
May
2020

RDA COVID19 Webinar Slides 12 May 2020

by Hilary Hanahoe

RDA COVID19 Presentation slides from Update and Status webinar - 12 May 2020 11 UTC

AttachmentSize
File COVID19-webinar-12May-2020.pptx5.64 MB
05
May
2020

RDA COVID19 Webinar Presentation 5 May 2020

by Hilary Hanahoe

Presentation slides from the RDA COVID-19 Webinar on Tuesday 5 May 2020 at 11 UTC.

AttachmentSize
File Webinar_5May.pptx7.17 MB
28
April
2020

RDA COVID-19 28 April Webinar Slides

by Hilary Hanahoe

Presentation slides from the RDA COVID-19 Update and Status Webinar from 28 April 2020

AttachmentSize
File COVID19-webinar-28April-2020.pptx4.38 MB
21
April
2020

RDA COVID19 21 April 2020 Webinar Slides

by Hilary Hanahoe

RDA COVID-19 working and subgroup update webinar slides as presented on 21 April 2020

AttachmentSize
File COVID19-webinar-21April-2020.pptx3.57 MB
17
April
2020

European Commission H2020 Guidelines for open access to publications, data and other research outputs

by Hilary Hanahoe

On 8 April 2020, the European Commission (EC) released a set of guidelines for open access to publications, data and other research outputs for Horizon 2020 projects working on the 2019 coronavirus di

AttachmentSize
PDF icon H2020_Guidelines_COVID19_EC.pdf930.4 KB
14
April
2020

RDA COVID-19 Webinar 14 April

by Hilary Hanahoe

Slides from the RDA COVID-19 Working group and sub-groups status and progress update webinar on 14 April 2020.

AttachmentSize
File COVID19-webinar-14April-2020.pptx2.85 MB
07
April
2020

RDA COVID-19 Webinar 7 April 2020 Presentation

by Hilary Hanahoe

The presentation slides for the 7 April 2002 Webinar at 11 UTC.

AttachmentSize
File RDA COVID-19 Webinar 7 April 2020.pptx2.94 MB
04
April
2020

Emergency Management Protocol Covid19

by Paola Di Maio

The Nature of the Covid19 pandemic taking place globally is unprecedented in scale, pace of the spread, and very high mortality rate. The Covid19 pandemic is not only proving challenging for medical research, with teams searching for vaccines and clinical treatments using the latest genomic approaches but also, and especially for emergency medicine. Increasing numbers of people showing Covid19 infection symptoms have been approaching ER departments worldwide, shortages in diagnostic kits as well as in treatment medications facilities are contributing to growing mortality rates Mixed with political spats, disinformation, censorship and hyper surveillance, the current situation triggered by Covid19 has become a matter of global security well exceeding the medical emergency. By combining experiences in clinical field practice and phytotherapy, this Communication article intends to share a first responder’s approach to treating patients showing mild to moderate and sever symptoms, using widely available materials and equipment, in the absence of medications and clinical facilities

AttachmentSize
PDF icon EM protocol.pdf94.91 KB

Pages